MiMedx Swings to a Q2 Loss as Wound Sales Plunge 61%; Announces $350M Sanara MedTech Acquisition
MDXG sits 37% above its 52-week low of $3.025.
Summary
MiMedx posted a Q2 net loss of $14.8M as Wound sales cratered 61% on Medicare changes, while Surgical grew 15%. Concurrently, the company announced a $350M acquisition of Sanara MedTech, financed with $300M in new debt.
Key Events · Earnings and Guidance · MDXG
-
Q2 Loss on Wound Collapse
A net loss of $14.8M ($0.10/share) compares with net income of $9.6M a year ago. Wound sales fell 61% to $25.1M, reflecting Medicare reimbursement changes that took effect January 1, 2026. Surgical sales rose 15% to $39.3M.
-
Gross Margin Compressed
Gross margin dropped to 69.0% from 81.1%, driven by lower Wound pricing and higher manufacturing costs. Cost of sales increased 7% despite the revenue decline.
-
Credit Losses Spike
Credit loss expense jumped to $5.3M in Q2 from $0.4M a year ago, tied to deteriorating credit quality of legacy customers. The allowance for credit losses now stands at $14.8M against $56.1M in gross receivables.
-
$350M Sanara MedTech Acquisition
Subsequent to quarter-end, MiMedx agreed to acquire Sanara MedTech for ~$350M in cash and stock ($302M cash, 4.4M shares). The deal is expected to close in 2026, funded by a $300M Hayfin term loan at SOFR + 6.25%.
Analysis · MDXG · Industrial Applications And Services
Medicare reimbursement cuts have gutted MiMedx's core Wound business, pushing the company to a $14.8M net loss and erasing 12 points of gross margin. In response, management is pivoting aggressively: Surgical sales grew 15%, and a transformative $350M acquisition of Sanara MedTech was just unveiled, backed by a $300M term loan. While the deal reshapes the company's future, it also layers on significant leverage and integration risk at a moment when legacy operations are under severe pressure.
At the time of this filing, MDXG was trading at $4.15 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $630M. The 52-week trading range was $3.03 to $7.99. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.